Scott Burger Joins Elucid as Chief Commercial Officer

Elucid Inc. has hired Scott Burger as chief commercial officer. He joins the firm as Elucid is expanding the commercial footprint of its PlaqueIQ technology, the only U.S. Food and Drug Administration (FDA)-cleared plaque analysis software to identify and match CT images to patient tissue samples, simulating the view pathologists see under a microscope.
 
“We welcome Scott to our senior leadership team at this important time of growth for the company. His vast range of leadership experiences in the medical device and services space is exactly what we are looking for to take us to the next level as we increase our commercial footprint,” Elucid CEO Blake Richards said. “Scott’s knowledge and track record of success will be vital for Elucid as we launch several next generation plaque and FFRCT products in the coming months.”
 
Burger brings more than 15 years of leadership experience and will lead sales, marketing, market access and customer success. He joins Elucid from CorVista Health, a non-invasive cardiac diagnostics company that combines advanced disciplines of mathematics, physics and machine-learning to reshape existing care pathways. Prior to his tenure at CorVista, Scott was commercial vice president at HeartFlow, and previously held leadership roles at Johnson & Johnson, superDimension, Bard, and ConvaTec.
 
“Being at the forefront of what’s next in cardiovascular care is my passion, and I am thrilled to join Elucid at this exciting time of growth,” Burger said. “Elucid’s next generation FFRCT and plaque analysis has the potential to change how cardiovascular disease is managed and I look forward to working with the talented team to accelerate the adoption of Elucid’s groundbreaking technology.”
 
Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology. Its AI-powered imaging analysis software, PlaqueIQ, is designed to deeply understand the biology of cardiovascular disease. The only FDA-cleared analysis software that objectively quantifies plaque morphology based on actual biology (validated against tens of thousands of tissue samples), PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid Plaque Analysis software is available for commercial use in the United States and South Korea.